AHCPR Issues Colorectal Cancer Screening Evidence Report

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 3
Volume 6
Issue 3

ROCKVILLE, Md--In the first report issued under its new Evidence-based Practice Initiative, the Agency for Health Care Policy and Research (AHCPR) has reaffirmed that early detection and treatment provide the primary means of preventing death from colorectal cancer.

ROCKVILLE, Md--In the first report issued under its new Evidence-basedPractice Initiative, the Agency for Health Care Policy and Research (AHCPR)has reaffirmed that early detection and treatment provide the primary meansof preventing death from colorectal cancer.

Among the conclusions of the report, based on a review of 3,500 citationsfrom the scientific literature (1966 to 1994):

  • Use of fecal occult blood testing followed by diagnostic evaluationand treatment for positive tests can cut colorectal cancer mortality by15% to 33%.
  • A 60-cm flexible sigmoidoscopy identifies nearly all cancers and polypsgreater than 1 cm in diameter and 75% to 80% of small polyps.
  • Sigmoidoscopy screening can reduce colorectal cancer mortality riskby 59% to 80%.
  • Indirect evidence supports the use of double-contrast barium enemain screening for colorectal cancer.
  • While screening colonoscopy offers the potential to both identify andremove cancers and premalignant lesions, no studies completed to date showan associated mortality reduction.
  • Detecting and removing polyps reduces the incidence of colorectal cancer,and removing early cancers lowers mortality. Although both double-contrastbarium enema and colonoscopy detect polyps and tumors, they have not beenstudied as screening tests.

  • © 1997 by PRR, Inc. All rights reserved.
Recent Videos
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
Related Content